StemCell Therapy

Second Sight Medical Products (NASDAQ:EYES) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Wednesday, Zacks.com reports. The brokerage presently has a $1.00 price target on the medical device companys stock. Zacks Investment Researchs price target would suggest a potential upside of 20.48% from the companys previous close.

According to Zacks, Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California.

Separately, ValuEngine downgraded shares of Second Sight Medical Products from a hold rating to a sell rating in a report on Thursday, November 14th.

Shares of EYES stock traded down $0.03 on Wednesday, hitting $0.83. 40 shares of the stock traded hands, compared to its average volume of 204,239. The firm has a market cap of $104.32 million, a price-to-earnings ratio of -1.60 and a beta of 2.27. Second Sight Medical Products has a 52 week low of $0.63 and a 52 week high of $1.21. The firm has a 50 day simple moving average of $0.82 and a two-hundred day simple moving average of $0.81. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.83 and a quick ratio of 2.66.

Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings data on Thursday, November 14th. The medical device company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.06). The firm had revenue of $0.47 million for the quarter, compared to the consensus estimate of $0.94 million. Second Sight Medical Products had a negative net margin of 743.86% and a negative return on equity of 201.34%. Sell-side analysts forecast that Second Sight Medical Products will post -0.29 EPS for the current year.

About Second Sight Medical Products

Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.

Read More: How is the LIBOR rate calculated?

Get a free copy of the Zacks research report on Second Sight Medical Products (EYES)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
Second Sight Medical Products (NASDAQ:EYES) Stock Rating Upgraded by Zacks Investment Research - Riverton Roll

This entry was posted on November 22, 2019 at 5:51 pm and is filed under Eye Sight & Vision. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |